Leveraging Tumor Organoids & RWD to Generate Multimodal Insights for Drug Development
Time: 9:00 am
day: Day One AM
Details:
- Showcasing Tempus’ platform of 3D patient-derived organoids (PDOs) grounded in de-identified real-world clinical data to address high failure rates and increased costs in drug development due to a lack of robust preclinical models in the discovery and translational space
- With one of the largest, pan-indication PDO repositories in the industry, Tempus’ portfolio of fixed screening panels supports research questions across a range of modalities including small molecules, ADCs, and cell therapies
